Skip to main content

Branded

  • Study finds fourfold increase in OxyContin prescriptions dispensed near U.S.-Canada border tunnel

    NEW YORK — The launch of a tamper-resistant formulation of a popular opioid painkiller in the United States, but not in Canada, may have influenced a spike in dispensing rate of the original at pharmacies in Canadian border cities, according to a study.

  • Staples survey: Eight-in-10 workers sick with the flu still come to work

    FRAMINGHAM, Mass. – Nearly 80% of office workers polled come to work even when they know they are sick — an increase of 20% over last year — according to the third annual "Flu Season Survey" from Staples. 

  • FDA approves new strength of HIV drug

    TITUSVILLE, N.J. — The Food and Drug Administration has approved a new strength of a drug for HIV made by Johnson & Johnson, the drug maker said.

    J&J subsidiary Janssen Therapeutics announced the approval of an 800-mg formulation of Prezista (darunavir) as a once-daily treatment for HIV. The drug is designed to be taken with food at the same time as ritonavir and in combination with other HIV drugs.

  • FDA panel recommends approval for two Novo Nordisk insulin products

    BAGSVÆRD, Denmark — A Food and Drug Administration panel has voted to support two experimental insulin treatments made by Novo Nordisk, the Danish drug maker said Thursday.

    Novo Nordisk said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee had voted 8-to-4 in favor of approval for insulin degludec and a combination treatment containing insulin degludec and insulin aspart.

  • GSK awards $200,000 in grants to nonprofit healthcare organizations reaching underserved communities

    RESEARCH TRIANGLE PARK, N.C. — GlaxoSmithKline on Thursday announced the five recipients of its annual GlaxoSmithKline IMPACT Awards. In total, the North Carolina and Philadelphia-area healthcare nonprofit organizations will receive $200,000 in grant funding ($40,000 each) for providing access to healthcare for the underserved in their communities.

  • FDA panel recommends approval for Novartis Cushing's disease drug

    EAST HANOVER, N.J. — A Food and Drug Administration expert panel has voted unanimously in favor of approval for a Novartis drug for a rare endocrine disorder.

  • FDA accepts Merck application for insomnia drug

    WHITEHOUSE STATION, N.J. — The Food and Drug Administration has accepted an application from Merck for an experimental drug for insomnia, the drug maker said Thursday.

    Merck announced the the FDA's acceptance of its regulatory filing for suvorexant, which the FDA's Controlled Substances Staff will review while the agency is reviewing the application.

  • MonoSol Rx, BiondVax form partnership to develop oral-film vaccine delivery

    WARREN, N.J. — A company developing drug-delivery technology based on films inserted into the mouth and a company developing a flu vaccine have entered a deal to combine their products.

    MonoSol Rx on Wednesday announced that it had entered a partnership with Israel-based BiondVax to combine MonoSol's PharmFilm technology with BiondVax's universal flu vaccine, M-001, to create a way to deliver vaccines without needles. MonoSol Rx co-president and CEO A. Mark Schobel said using his company's technology for vaccinations could lead to increased acceptance of flu vaccination.

X
This ad will auto-close in 10 seconds